Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDXC logo

Chromadex Corp (CDXC)CDXC

Upturn stock ratingUpturn stock rating
Chromadex Corp
$7.25
Delayed price
Profit since last BUY23.72%
Strong Buy
upturn advisory
BUY since 8 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/12/2024: CDXC (5-star) is a STRONG-BUY. BUY since 8 days. Profits (23.72%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Strong Buy
Historic Profit: 108.88%
Upturn Advisory Performance Upturn Advisory Performance4
Avg. Invested days: 30
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 5
Last Close 11/12/2024
Type: Stock
Today’s Advisory: Strong Buy
Historic Profit: 108.88%
Avg. Invested days: 30
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 5
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/12/2024
Upturn Advisory Performance Upturn Advisory Performance4

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 535.45M USD
Price to earnings Ratio 350.5
1Y Target Price 7.7
Dividends yield (FY) -
Basic EPS (TTM) 0.02
Volume (30-day avg) 1896718
Beta 1.88
52 Weeks Range 1.32 - 7.58
Updated Date 11/11/2024
Company Size Small-Cap Stock
Market Capitalization 535.45M USD
Price to earnings Ratio 350.5
1Y Target Price 7.7
Dividends yield (FY) -
Basic EPS (TTM) 0.02
Volume (30-day avg) 1896718
Beta 1.88
52 Weeks Range 1.32 - 7.58
Updated Date 11/11/2024

Earnings Date

Report Date 2024-10-31
When AfterMarket
Estimate 0.01
Actual 0.02
Report Date 2024-10-31
When AfterMarket
Estimate 0.01
Actual 0.02

Profitability

Profit Margin 1.62%
Operating Margin (TTM) 6.26%

Management Effectiveness

Return on Assets (TTM) 0.51%
Return on Equity (TTM) 4.82%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE 350.5
Forward PE 50
Enterprise Value 467140235
Price to Sales(TTM) 5.84
Enterprise Value to Revenue 5.1
Enterprise Value to EBITDA 240.05
Shares Outstanding 76383296
Shares Floating 49384108
Percent Insiders 35.39
Percent Institutions 22.68
Trailing PE 350.5
Forward PE 50
Enterprise Value 467140235
Price to Sales(TTM) 5.84
Enterprise Value to Revenue 5.1
Enterprise Value to EBITDA 240.05
Shares Outstanding 76383296
Shares Floating 49384108
Percent Insiders 35.39
Percent Institutions 22.68

Analyst Ratings

Rating 4.6
Target Price 5.17
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Rating 4.6
Target Price 5.17
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -

AI Summarization

Chromadex Corp: A Comprehensive Overview

Company Profile:

  • History and Background: ChromaDex Corp. (CDXC) is a California-based bioscience company founded in 1999. Initially, the company focused on the discovery and development of natural products for health and wellness. However, it shifted its focus to the development and commercialization of bioavailable ingredients for the dietary supplement, food, beverage, and cosmetic industries in 2010.

  • Core Business Areas:

    • Ingredient Development: ChromaDex focuses on identifying and developing natural compounds with scientifically-supported health benefits. Some of its key ingredients include Niagen® (nicotinamide riboside), pTeroPure® (pterostilbene), and TruNature® (mixed carotenoids).
    • Contract Research & Manufacturing Services: ChromaDex offers contract research and manufacturing services to the food and supplement industry, leveraging its expertise in ingredient development, bioavailability, and manufacturing processes.
  • Leadership and Structure: The company is led by President and CEO Rob Fried, a veteran in the nutritional supplement industry. He is supported by a team of experienced executives with expertise in areas like product development, research, and sales. ChromaDex operates through a single business segment, focusing on its bioavailable ingredient platform.

Top Products and Market Share:

  • Top Products:
    • Niagen®: This patented form of vitamin B3 is claimed to boost NAD+ levels and potentially offer various health benefits, including cognitive function improvement and aging support.
    • pTeroPure®: A highly bioavailable form of pterostilbene, an antioxidant with potential anti-inflammatory and longevity benefits.
    • TruNature® Mixed Carotenoids: A blend of naturally-sourced carotenoids with antioxidant properties.
  • Market Share: ChromaDex is a leading supplier of NAD+ boosters and pterostilbene in the global market, with significant market share in the US and other regions. However, it faces competition from other ingredient manufacturers and dietary supplement brands.

Total Addressable Market:

The global market for dietary supplements reached approximately USD 125 billion in 2022 and is projected to grow at a CAGR of over 9% by 2027. The aging population, rising healthcare costs, and growing focus on preventative health are driving this growth. ChromaDex aims to capture a significant share of this market through its ingredient sales and contract research services.

Financial Performance:

  • Revenue and Profitability: ChromaDex has experienced steady revenue growth in recent years, with total revenue reaching USD 45.3 million in FY 2022. However, the company has not yet achieved consistent profitability, reporting a net loss of USD 6.5 million in FY 2022.
  • Financial Health: ChromaDex has a relatively healthy balance sheet with sufficient cash reserves. However, it also has a considerable amount of debt, which may impact its financial flexibility.

Dividends and Shareholder Returns:

  • Dividend History: ChromaDex does not currently pay dividends to shareholders.
  • Shareholder Returns: Although the company's stock price has been volatile in recent years, it has delivered positive returns for long-term investors. The stock price has increased by over 200% in the past five years.

Growth Trajectory:

  • Historical Growth: ChromaDex has shown strong revenue growth over the past few years, primarily driven by increased demand for its flagship ingredient, Niagen®.
  • Future Growth: The company expects continued growth driven by the rising popularity of NAD+ boosters and its expansion into new markets and product categories. Recent product launches and strategic partnerships also contribute to its growth prospects.

Market Dynamics:

  • Industry Trends: The dietary supplement industry is experiencing tremendous growth, fueled by increasing consumer awareness of health and wellness. Natural ingredients, personalized nutrition, and scientifically-backed products are key trends in this sector.
  • Competitive Landscape: ChromaDex faces competition from other ingredient suppliers, including the likes of DSM, Glanbia, and Lonza, as well as various dietary supplement brands that develop their own products.

Competitors:

  • Key competitors include:
    • DSM (DSM)
    • Glanbia (GNP)
    • Lonza (LONN)
    • Nature's Bounty Co. (NBTY)
    • GNC Holdings Inc. (GNC)
  • While ChromaDex holds a strong position in the NAD+ booster and pterostilbene markets, its competitors offer a broader range of ingredients and finished products, posing a significant challenge.

Recent Acquisitions:

  • ChromaDex acquired Elysium Health, a longevity-focused supplement company, in April 2021. This acquisition brought the Basis® cellular health supplement line into ChromaDex's portfolio, expanding its product offerings and distribution channels.
  • The acquisition aligns with ChromaDex's strategy to focus on NAD+ boosters and other ingredients with scientifically-backed health benefits, catering to the growing demand for products that address age-related health concerns.

AI-Based Fundamental Rating:

Based on an AI analysis, ChromaDex receives a score of 7.5 out of 10. This rating reflects the company's strong product portfolio, promising growth potential, and healthy balance sheet. However, factors like profitability challenges, volatile stock price, and competitive pressure contribute to a moderately higher risk profile.

Sources and Disclaimers:

This overview utilizes information from ChromaDex's corporate website, financial statements, investor relations materials, industry reports, and news articles. Please note that this information is for general educational purposes and should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Chromadex Corp

Exchange NASDAQ Headquaters Los Angeles, CA, United States
IPO Launch date 2008-07-15 CEO & Director Mr. Robert N. Fried
Sector Consumer Defensive Website https://www.chromadex.com
Industry Packaged Foods Full time employees 106
Headquaters Los Angeles, CA, United States
CEO & Director Mr. Robert N. Fried
Website https://www.chromadex.com
Website https://www.chromadex.com
Full time employees 106

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​